Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s traded shares stood at 1.98 million during the last session, with the company’s beta value hitting 1.44. At the close of trading, the stock’s price was $15.10, to imply an increase of 9.82% or $1.35 in intraday trading. The CNTA share’s 52-week high remains $17.25, putting it -14.24% down since that peak but still an impressive 65.89% since price per share fell to its 52-week low of $5.15. The company has a valuation of $1.71B, with an average of 1.14 million shares in intraday trading volume over the past 10 days and average of 432.09K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Centessa Pharmaceuticals plc ADR (CNTA), translating to a mean rating of 1.29. Of 6 analyst(s) looking at the stock, 0 analyst(s) give CNTA a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.42.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
After registering a 9.82% upside in the last session, Centessa Pharmaceuticals plc ADR (CNTA) has traded red over the past five days. The 5-day price performance for the stock is 3.42%, and 37.15% over 30 days. With these gigs, the year-to-date price performance is 89.70%. Short interest in Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) saw shorts transact 1.1 million shares and set a 3.35 days time to cover.
The extremes give us $19 and $20 for target low and target high price respectively. As such, CNTA has been trading -32.45% off suggested target high and -25.83% from its likely low.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
Looking at statistics comparing Centessa Pharmaceuticals plc ADR share performance against respective industry, we note that the company has underperformed competitors. Centessa Pharmaceuticals plc ADR (CNTA) shares are 39.17% up over the last 6 months, with its year-to-date growth rate lower than industry average at -2.55% against 20.00%. Revenue is forecast to shrink -5.00% this quarter before falling -18.40% for the next one.
CNTA Dividends
Centessa Pharmaceuticals plc ADR has its next earnings report out in October. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
Centessa Pharmaceuticals plc ADR insiders hold 1.76% of total outstanding shares, with institutional holders owning 87.94% of the shares at 89.52% float percentage. In total, 87.94% institutions holds shares in the company, led by MEDICXI VENTURES MANAGEMENT (JERSEY) LTD. As of 2024-06-30, the company held over 19.96 million shares (or 19.9856% of shares), all amounting to roughly $180.27 million.
The next major institution holding the largest number of shares is GENERAL ATLANTIC, L.P. with 9.68 million shares, or about 9.6927% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $87.43 million.
